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Molecular Dosimetry of Aflatoxin
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the Multifactorial Etiopathogenesis of
Primary Hepatocellular Carcinoma with
Particular Reference to Hepatitis B Virus
by Christopher P. Wild,' Leon A. M. Jansen,' Lucyna
Cova,2 and Ruggero Montesano'
Aflatoxin exposure andhepatitisBvirusinfection havebeenimplicatedasmajorriskfactorsforprimaryhepatoceOlular
carcinoma (PHC) inhigh-incidenceregionsoftheworld. Investigationsusingtheassayofaflatoxinboundtoperipheral
bloodalbuminhaveshownthatexposurecanoccurthroughoutthelifespanoftheindividual,includingduringtheperinatal
period, inhigh-incidence areassuchasTheGambia, Senegal, Kenya, andThePeople'sRepublicofChina. Thepossibility
ofmeasuringaflatoxinexposureattheindividuallevelpermitsaninvestigationoftheputativemechanismsofinteraction
ofthiscarcinogenwith HBVintheetiopathogenesis ofPHC. Aninalmodels, e.g., PekinduckandHBV-transgenicmice,
have also been used to study thesequestions, and the available data are reviewed.
Introduction
Primary hepatocellular carcinoma (PHC) is one ofthe most
common cancers worldwide, with ahighmortality among cases.
Hepatitis B virus (HBV) infection and aflatoxin exposure have
been identified as majorrisk factors in thehigh-incidence areas
of Africa and Southeast Asia (1), and programs to vaccinate
against HBV have been implemented in various countries, in-
cluding TheGambia, withtheperspectiveofobserving areduc-
tion in the incidence ofthis cancer in those areas (2). The car-
cinogenicity ofaflatoxin B1 (AFB,) inhumans has beendifficult
to assess, despite the wealth ofresearch onthiscompound since
its chemical identification intheearly 1960s (3). Although the
carcinogenicity in animals, including primates, is well
established, the epidemiological data for risk ofPHC are in-
evitably less conclusive. However, the data were sufficiently
strong for an IARC Working Group (4) to conclude that there
was "sufficient evidence of carcinogenicity in humans"
(classified Group 1). Theepidemiological data aremainly con-
fined toecological correlation studies(I), andthelimitationof
this type of study design is well recognized. Studies both in
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Africa(5)andthePeople'sRepublicofChina(6)controllingfor
HBV carrier rates have suggested animportantcontribution of
aflatoxintoPHCrates. Morerecently, alargecorrelationstudy
inChinareportednoassociationbetweenPHCandexposureto
aflatoxin, asdeterminedbydetectionofaflatoxinmetabolites in
theurine(7); theconclusionsofthisstudyhavebeenquestioned,
mainlybecauseofthemethodusedtoassessaflatoxinexposure
(8). Recent data on liver tumors from China (9) and southern
Africa(10) haveaddedafurtherdimension tothediscussion in
suggesting thatthehighfrequencyofaspecificpointmutation(G
toTtransversion)incodon249ofthepS3tumor-suppressorgene
in PHC fromtheseareasis related toAFB, exposure, which is
reportedlyhigh inthesepopulations. Thismutationisapparently
not related to HBV infection (11,12).
Inallthestudiesdescribedabove, twolimitationsareevident.
First, thereisanotableabsenceofstudiesconsideringexposure
at the individual level (e.g., case-control and cohort studies),
because ofan absence ofappropriate exposure markers at that
level, and second, there isadifficulty inassessing an indepen-
dent risk for aflatoxin in the presence of a strong, specific
association between HBVand PHC. Thelatterdifficulty is ex-
acerbatedbythelackofunderstanding atamechanistic level of
thepossiblenatureoftheinteractionbetweenaflatoxinandHBV
infection intheetiopathogenesis ofPHC. Itis still notevident if
thedevelopmentofPHCinHBVchroniccarriersistheresultof
specific genetic changes attributable to HBV or indirect (non-
specific) mechanisms resulting from recurrent cell deathWILDETAL.
and proliferation. Research to overcome the above limitations
willbevaluable inprovidingdatatoaccurately assesstheriskof
developing this cancerfrom exposure toaflatoxinandwouldalso
contribute toeffectiveplanningofintervention toreduceaflatoxin
exposure.
Recently, anumberofmethods toquantitate exposure atthein-
dividuallevelhavebeendeveloped(13,14). Specifically, the assay
ofaflatoxinbound toperipheralbloodalbumin(15-19)hasbeen
shown tobesuitablefor useinepidemiological studiesofaflatox-
inandpotential applicationsofthe methodhavebeendescribed
(18,20,21). Inaddition, several animal models areavailable to
study thepossible mechanismofinteractionbetweenHBVand
aflatoxin.
This paper describes the information that has been derived
aboutthe level anddurationofhuman exposure toaflatoxin us-
ing the measurement ofthe aflatoxin-albumin adduct. These
data are presented in relation to the possible stages and mech-
anismsofinteractionwithHBVinfectionand arediscussedinthe
light ofrecentdata from animal model and field studies.
Aflatoxin-Albumin Adducts in Human
Sera
The assay that has been used in our laboratory to assay
aflatoxin-albumin adductshasbeendescribedindetail (16-18).
Briefly, albumin is precipitated from serum or plasma, quan-
titated, and aknown amount is enzymatically hydrolyzed. The
aflatoxin residues fromthehydrolysis arepurifiedeither bySep-
pakC18cartridgesbeforequantificationin anELISAor by anad-
ditional step on an aflatoxin antibody affinity column before
analysis ofamajor adduct, AFB,-lysine, by HPLC with fluo-
rescence detection. Attention has been drawn to the fact that
hydrolysiswillyield anumberofdifferentaflatoxinresiduesand
thatthequantitation inimmunoassay willdepend ontheaffini-
tyoftheantibody foreachoftheseresidues(22). Asimilarpoint
is relevant toquantitationofurinary aflatoxinmetabolites (22).
Intheapproachwhich wehaveused,a)theantibodyusedinthe
immunoassay appears torecognizethehydrolysisproductswith
the same affinity as the AFB,-lysine standard (18) andb) con-
firmation ofimmunoassay results by HPLC-fluorescence has
demonstrated agoodcorrelationbetween the measuresoftotal
hydrolysis products andAFBI-lysine (16).
Serafrom anumberofdifferenthumanpopulations havebeen
assayed in anumberofseparatestudies, and a summaryofthese
dataisgiveninTable 1. Someobservations onthesecollateddata
are discussed below.
First, exposure is significantly higher inboth West and East
AfricaandtheGuangxiregionofthePNople's Republic ofChina
than in Thailand, while in Europe aflatoxin adducts in all sera
have to datebeen nondetectable. The lower level ofadducts in
Thailand may reflectthefactthat, although aflatoxin ispresent
in Thai foods (24), the levels in rice, the staple for most ofthe
country, arerarely elevated. This contrasts with The Gambia,
Senegal, and Kenya, where the staple foods, groundnuts or
maize, are highly susceptible to aflatoxin contamination.
High levels (up to 100 x 106 nucleotides) ofaflatoxin-DNA
adducts have been reported in human liver tissues from in-
dividuals fromEurope(25), similartothose seenintissues from
Taiwan(26). Theoriginofthis exposureinEuropeisunknown,
Table 1. Aflatoxin-albumin adducts in humansera.'
No. ofsubjects withdifferent adduct levels,
pg AFB,-lysine eq./mg albumin
Country (n) <5b 5-25 26-50 51-75 76-100 >100
TheGambia
May (323) 7 53 76 49 40 98
November(67) 0 39 13 7 3 5
Senegal(29) 0 20 6 2 1 0
Kenya (91) 48 26 5 1 5 6
China
Guangxi(93) 28 35 13 6 2 9
Shandong(69) 69 0 0 0 0 0
Thailand (84) 73 10 1 0 0 0
France (44) 44 0 0 0 0 0
Pbland (30) 30 0 0 0 0 0
AFB,, aflatoxin B,.
aSomeofthes dataaretakenfromWildetal. (16). Thedatamereobtainedin
collaboration with: The Peopl's Republic ofChina: Y. Shun-Zhang, Public
Health School, Shanghai Medical University, Shanghai, and W Blot, National
CancerInstitute, Bethesda, MD; Thailand: P. Srivatanakul, NationalCancerIn-
stitute, Bangkok; The Gambia: S. J. Allen and H. Whittle, MRC, Fajara, The
Gambia; Kenya: D. Forman, ICRP, Oxford, UK; Senegal: P. Coursaget, Institute
ofVirology, Tours, France.
bLimitofdetection, 5 pg AFB,-lysine Eq/mg albumin.
and itis importantto confirm such findings. Thesensitivity of
theaflatoxin-albuminassay shouldallowdetectionofthelevels
ofaflatoxin exposure required to yield the liver DNA adduct
levelsreported, unlessthelatteraccumulateovermanyyears, and
itwouldbevaluabletoassesstheserumalbuminadductsinthese
individualsorinthepopulationsfromwhichtheyaredrawn. No
evidenceoffreeAFB1 inaseriesofserafromtheUKwasfound
(27).
Second, seasonalvariations inexposure mayoccuras seenin
TheGambiain Novemberand May (17). This requires further
considerationinthedesignoffuturefieldstudies. Third, strik-
inggeographicalvariations inexposureoccurwithinacountry
IntheGuangxiregionintheSoutheastofChina, 70% ofsubjects
had detectable levels ofadduct, whereas no subjects from the
northeasternprovinceofShandongwerepositive(unpublished
collaborative studies withJ. Chen, InstitutionofNutrition and
FoodHygiene, ChineseAcademyofPreventiveMedicine, Bei-
jing, and S. Z. Yu, Epidemiology Department, Public Health
School, Shanghai Medical University, Shanghai).
Exposuretoaflatoxinhasbeenobservedinallagegroupsthat
we have examined to date. Exposure was as high in Gambian
children(age3-8years)asinadults(17),anditisalsoknownthat
aflatoxin exposure at earlier ages can occur via breast milk
(28,29). Inthelattercase,metabolismofaflatoxinbythemother
reduces the child's exposure to less than 1% of the mothers
dietary intake (29), and the metabolites found in the milk,
althoughcarcinogenic, are less so than AFB, (30). Recently it
wasalsodemonstratedthattransplacentalexposuretoaflatoxin
occursinthispopulationwith levelsofaflatoxin-albuminadduct
in umbilical cord blood being 5-10 times lower than in the
mothers' venousbloodatthetimeofdelivery(31). Thisinutero
exposure to a mutagen, as well as exposure soon after birth,
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could be particularly relevant because the putative stem cell
population ("oval cells") could be mutated duringtheperiod of
liver cell differentiation (32). Subsequently, the cell prolifera-
tion occurring in the liverofHBV carriers with chronic, active
hepatitis could lead totheclonal expansionofthese initiatedcells
and tothe occurrence ofothergenetic changes leading to cancer.
It is ofinterest that in populations where aflatoxin exposure is
high, arepeatedobservation isthehighprevalenceofPHC com-
pared to hepatoblastoma in teenage children (33-35), whereas
the latter is normally more common in children.
The overall pattern ofaflatoxin exposure in TheGambia, for
example, is one ofchronic exposurethroughout the lifetime of
the individual, atthe samehigh level except for somereduction
during the perinatal period. The percentage ofthe population
who are chronic carriers ofHBV is also at a maximum by 2-3
yearsofageintheGambia(36). Thesedata onaflatoxin exposure
and HBV infection are summarized together with the age-
dependent incidence ofhepatocellularcarcinoma in The Gam-
bia in Figure 1. Exposuretoaflatoxin canthereforeprecede HBV
infection in The Gambia, and the two risk factors are present
from anearly age, givingthemaximumtimeperiodwithinwhich
they could interact. Data from animal model and field studies
directly pertaining to thequestion ofwhether aflatoxin andand
HBV do interact are presented below.
Animal Models
The interactionofaflatoxinand HBVhasbeenexamined in two
ofthe animal models forwhich hepadnaviruseshavebeen iden-
tified, namely, the Pekinduck and woodchuck (37). Inaddition,
various strains oftransgenic mice expressing providing an dif-
ferent humanHBV proteinshavebeendeveloped (38-40), pro-
viding an alternative approach. A study ofacute viral infection
of marmosets (Saguinus oedipomidas) treated with AFB, has
also been reported (41).
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FIGURE 1. Schematic representation ofaflatoxin exposure, hepatitis B virus
(HBV) infection, and liver cancer incidence in The Gambia. The Y-axis
represents the percentage ofthe rate fortheadultpopulationforaflatoxin ex-
posure (-----) and HBV infection (-). The 100% adult rate in The Gambia
for chronic Hepatitis B virus surface antigen carriers wastaken as 14% (36),
and the aflatoxin exposure data are from Wild et al. (17,31). The male age-
specific liver cancer rates per 100,000 (---) for The Gambia are from Bah
et al. (72), and inthis case the Y-axis is this incidence rate per 100,000. IU,
in utero.
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Carcinogenicity Studies
Threestudies havebeenpublishedinwhichthecarcinogenici-
tyofAFB1 hasbeencomparedinHBV-infectedandnoninfected
ducks (summarized in Table2). Inourlaboratory, two doses of
AFB, were used with a weekly administration. While an in-
creased mortality and more marked nontumor liver pathology
were observed in HBV-infected birds given AFB, compared to
those withoutthecarcinogen treatment, no statistically signifi-
cantdifferences in livercancer inductionoccurred (42). Other
studies (43,44) used different treatment regimens with higher
doses of AFB1 but also reported no significant difference in
tumorformation inducksadministeredAFBI inthepresenceor
absence ofHBV infection.
In all three studies the number ofducks is low, limiting the
strength ofthe conclusion, but taken overall the two factors do
not appear to act synergistically or additively to produce liver
tumors in this model. This may reflect the relatively mild liver
pathology observed in chronically infected ducks, with an
absence of immune-mediated destruction of HBV-infected
hepatocytes (44), comparedtothatseen inwoodchucks (45) or
humans. NolivertumorsoccurredinHBV-infectedducks inthe
absenceofAFB, intheaboveexperiments, andsuchcaseshave
only rarely been reportedelsewhere (46,47). Inthelattercases,
dietary exposuretoaflatoxincouldnotbeexcluded. Incontrast,
in the woodchuck, livertumors occurin almost 100% ofHBV-
infected animals (48). Carcinogenicity studies with AFB, and
HBV in woodchucks would be informative.
Intransgenic mice, twostudieshavedescribedtheinteraction
betweenchemical carcinogens and HBV intheinductionofliver
tumors, andtheseare summarized inTable 3. Themostconvin-
cing evidence to date from animal models for a synergism be-
tweenAFB, andHBV intheinductionoflivertumors isthework
ofSell etal. (49). Theseauthors usedtransgenic micecontain-
ing an HBV DNA fragment coding for the entire HBV surface
antigen (HBsAg) under transcriptional control of the mouse
albumingenepromotor(39). Inthislineoftransgenic micethere
is an accumulation of HBV large-envelope protein in the
hepatocytes, resulting insevere, chronicliverdamage. Allthese
mice develop PHC, in the absence of other treatment, at 20
months ofage (50). When treated withAFB,, a highly signifi-
cantnumberofadenomasandPHC wereobservedat 15 months
inthetransgenic micecomparedtoanabsenceofsuchtumors in
untreated transgenic mice (Table 3). Similar results were ob-
Thble2. Studiesonthe roleofAFB, andHBVinfection in inductionofliver
cancer in Pekin ducks.
AFBI, No. ofanimals
mg/kg HBVa with tumors Reference
0.08 - 3/10 (3 HCC, 1 ADE) Cova et al., 1990 (41)
0.08 + 3/6(3 HCC)
0.02 - 2/10 (1 HCC, 1 ADE)
0.02 + 0/13
0.2 - 3/4 (3 HCC) Cullen et al., 1990 (43)
+ 6/8 (3 HCC, I BC, 3 ADE)
0.1 - 2/8 (2 HCC) Uchida et al., 1988 (42)
0.1 + 0/8
Abbreviations: AFB,, aflatoxin B,; HBV, hepatitis B virus; HCC, hepato-
cellular carcinoma; ADE, adenocarcinoma; BC, biliary carcinoma.
aDucks wereeithercongenitally infected (42,44) or inoculatedwith HBV after
hatching (43).
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Table 3. Chemical hepatocarcinogenesis in HBV-transgenic mice.
No. mice
Plasmid Strain Carcinogen No. of withtumors
recombinant (sex) treatment mice ADE PHC Reference
HBV only C3H/He DEN 23 9 3 Draganietal.,
(M) 1989 (54)
None DEN 19 5 1
HBV only C3H/He DAB 12 5 1
(M)
None DAB 22 7 -
a ~~~~~b HBV+Alb C57BI/6 AFB,a 8 10 2 Sell et al.,
promoter (F) 1991 (48)
None AFB, 8 - -
HBV+Alb C57BI/6 DENC 8 9 2
promoter (F)
None DEN 10 - -
HBV+Alb C57B1/6 Phenobar- 4 - -
promoter (F) bitald
None Phenobar-
bital 5 - -
Abbreviations: HBV, hepatitis B virus; Alb, albumin; DEN,
dimethylnitrosamine; DAB, dimethylamino-azobenzene; AFB,, aflatoxin B,.
"Treatment was 2 Mg/g AFBI, administered three times at approximately
I-week intervals.
bTotal number ofPHC andadenomas in each group is recorded.
CTreatment was 50 Ag/g DEN administered as a single dose.
dTreatment was0.1% phenobarbital in the diet for I year.
tained withanotherhepatocarcinogen, diethylnitrosamine. The
characteristic ofthelineoftransgenicmiceusedinthisstudy is
thetoxicconcentration ofHBsAginthehepatocyte, whichleads
todirectdamagetothesecells. Inhumans, thelivercelldamage
due to HBV infection andthe resultantcellularproliferation are
probably due to mechanisms other than the accumulation of
HBsAg seenintheabovemodel. Nevertheless, acommonobser-
vation isthatliverdamageresulting fromarangeofinsultsthat
induce cell proliferation, e.g., HBV, hepatitis C virus (HCV),
alcohol, genetic disorders, is associated with development of
PHC in humans (51-54), and therefore this model may be
representative ofthe human situation.
Dragani etal. (55) reported a less marked butsignificant in-
crease in livertumors inadifferent lineoftransgenic malemice
treated withdiethylnitrosamine and anotherhepatocarcinogen,
dimethylaminoazobenzene. In these mice no liver pathology
results fromthepresenceofthetransgene(38), andtheincreased
carcinogenicity is seenintheabsenceofliverdamage. Another
difference inthis study compared tothatofSell etal. (49) was
thatasingledoseofcarcinogenwasadministeredat7daysofage,
whereas in the latter study carcinogen treatment started at 3
months, a time at which moderately severe chronic hepatitis is
already present (50).
Onestudyinmarmosets reportstheinteractionbetweenAFBJ
(200 ug/kg body weight; 5 days per week) and viral hepatitis
(41). Infection was acute using an inoculum from a human
hepatitis casethathadbeenseriallypassagedin marmosets(56),
andanimals wereinfected6weeksafterthe startofAFBI treat-
ment. Of12 marmosetsgivenAFB, alone, onedeveloped aPHC
after50 weeks, whereas in the grouphaving the viral infection
inaddition, 2of12developedPHCafter87 weeks. Cirrhosisand
portal fibrosis were most severe inthe groupreceiving AFB, and
hepatitis infection. Notumors were seeninanimalsreceiving on-
ly virus or in untreated animals. It was also observed that cir-
rhosis wasinduced inthemarmosets withAFB1, whereasinthe
rat this is notthe case.
Carcinogen Metabolism
One hypothesis regarding a mode of interaction between
aflatoxin and HBV is that viral infection could alter aflatoxin
metabolism, eithertheactivation tothe reactiveepoxide orthe
detoxificationreactions (conjugation toglutathione, hydroxyla-
tion, etc.). Someearly workwithhumanliverbiopsies suggested
anincreasedin vitro activation ofAFB, in casesofmild, chronic,
activehepatitisbut notin more severe cases (57). These studies
have been more extensively pursued in woodchucks and the
resultsrecently summarized (58). Astatistically significantin-
crease in activation ofthetryptophan pyrolysate, Trp-P-2, was
observed inHBVcarriers, and ahigherbutnotsignificantactiva-
tion of AFB1 was reported. In addition, the level of reduced
glutathione inliversofHBV-positiveanimals waslower, which
could contribute to a higher exposure of DNA to active car-
cinogen metabolites.
InapreliminaryexperimentinPekinducksin vivo, weobserved
alowerlevel ofAFBI-DNA adducts inthe livers ofchronically
HBV-infected compared tononinfected birdsafter asingledose
ofAFB, (42). In more recent studies we used newly hatched
Pekinducklings. Ducklings weredividedintofourgroupsoffive
ducklings with groups 1 and3 infectedwith HBV onday 3 after
hatching. Ondays2 to9inclusive, groups 1 and2 received2 ug
AFB,/kgbody weight, while groups3 and4receivedsolvent on-
ly. Allducklings weretreatedwith [3H]AFB1 onday 13(2 tg/kg)
and were sacrificed24hrlater. The amountofaflatoxin-adducts
in serumalbuminandliverDNA werequantitatedbydetermin-
ingthelevelofradioactivityboundtothesemacromolecules, and
thedata arepresented inTable4. Viral infectionhad noeffect on
adduct levels in liver DNA. This is in contrast to the data in
chronically infected ducks (42) mentioned above. There was a
trend toward higher serum albumin binding in HBV-infected
ducklings, butthese levels are affectedby asignificantdecrease
Table 4. Studiesoftheinteraction ofHBV infection andaflatoKin exposure in Pekin ducks.a
P mHBV-DNA, Pretreatment Liver DNA adduct, AF-serum protein adduct, Serum protein, ng DHBV-DNA/mg
Group AFB, HBV pg AF/mg DNA ± SEM pg AF/mgprotein ± SEM mg/mL ± SEM liver DNA ± SEM
I + + 34.94 ± 5.6 15.1 ± 1.7 24.3 ± 1.9 20.1 ± 3.7
2 + - 32.14 ± 4.4 11.9 ± 1.1 32.7 ± 1.8
3 - + 23.71 3.7 15.2 ± 1.7 21.5 ± 1.2 24.0 ± 3.8
4 - - 26.52 ± 3.1 14.0 ± 0.7 28.4 ± 1.4
Abbreviations: HBV, hepatitis B virus; AFBI, aflatoxin B,, AF, aflatoxin.
aTreatment protocols are described in the text. AFBI wasadministered IP indimethylsulfoxide (21sgAFB,/mL DMSO; I mL perkg body weight). Viral DNA
wasdeterminedbydenaturationandneutralization, followedbyDNA-spothybridization asdescribedbyCovaetal. (42). Statisticalanalysiswasbyanalysisofvariances
(ANOVA test).
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FIGURE 2. Variation ofthe mean serumduckhepatitis B virus-DNA concen-
trations with time. The experimental details are given in the text.
in serum protein concentrations in infected ducklings (Table 4).
The pretreatment withAFB, increased theaflatoxin liver DNA
binding, although the difference is only of borderline sig-
nificance (p = 0.06; groups 1 and 2 compared to 3 and4). This
finding is different from observations in ratswherepretreatment
with AFBI led to a decrease inAFBI-DNA adducts in theliver,
in this case as a result of increased glutathione-S-transferase
levels (59,60).
The above results are inconclusive as to the influence ofHBV
onthe balance ofaflatoxin activation and detoxification. Asthe
cytochrome P-450 enzymes involved inaflatoxin metabolism are
identified and noninvasive markers become available for use in
vivo (61,62), studying the influence of HBV on aflatoxin me-
tabolism is becoming more feasible.
Other Parameters
Little information is available onotherpotential ways in which
aflatoxin and HBV may influence eachothers' biological effects.
One hypothesis is that AFBI exposure could alter viral replica-
tion and/or integration as has been discussed for other vir-
al/chemical interactions (63). In our study ofducklings describ-
ed above, wealso measured HBV-DNA in the seraand livers of
ducklings that received AFBI from one day prior to HBV in-
oculation and for 6 days after inoculation. There were no dif-
ferences in thedaily meanlevels ofHBV-DNA inthe serum (Fig.
2), in the maximum serumviral concentrations (seen ondays 9-
11 after hatching) or in the concentration at the time ofsacrifice
on day 14 (data not shown). The viral DNA per microgram of
liver DNA was alsodetermined on day 14 (Table 4) but no signifi-
cant differences were found. Again these results were in contrast
to our observations in chronically infected adult ducks where
viral DNA titers in the sera and livers ofAFBI-treated ducks
tended to be higher than untreated ducks (42). These results
merit furtherinvestigation, taking into accounttheimmune status
oftheducks, the liver pathology, and theeffects ofchronic AFB,
exposure. Ofinterest is the report by Ronai and Weinstein (64)
that DNA damage induced by UV irradiation can induce a trans-
acting protein that alters viral DNA replication.
Field Studies in Humans
There are indications ofan interaction between aflatoxin and
HBV from epidemiological studies. Several studies have shown
geographical correlations between dietary AFB, and PHC in
areas where the HBsAg carrier rates are not significantly dif-
ferent (5,6). In addition, an important recent study showed a
synergistic interactionbetweenHBVandaflatoxininaprospec-
tivecohortstudyinChina(65). Anotherinterestingstudyshowed
an earlier onset of PHC in rural compared to urban South
AfricanBlacks withsimilarHBV status inthetwogroups (35).
All subjects had spenttheearly partoftheir lives in rural areas
but the "urban" group had migrated to the cities in late
adolescence orearly adulthood. The suggestion was made that
greater likelihoodofexposure toaco-carcinogen suchasaflatox-
incouldoccurinarural setting. This suggeststhatinaddition to
theimportanceofaflatoxinactingatanearly stageofhepatocar-
cinogenesis, itmay also actatalater stage. Theobservations of
earliertumoronsetinHBVcarriersexposedtoAFB, (oranother
carcinogen) areofinterest with respect to the dataofSell et al.
(49) mentionedabove. Other studies inMozambique have also
suggested an action of aflatoxin at a late stage of hepatocar-
cinogenesis (34). ThepS3mutation spectra(66) inlivertumors
occurring indifferentagegroupscouldbeinformative inassess-
ingtheroleofaflatoxinandHBV infection inthevarious stages
ofPHC development.
Ourlaboratory has investigated HBVandaflatoxin exposure
in two studies in The Gambia, West Africa. In a study of323
children intheFarafenniregionofthecountry, weexaminedthe
association attheindividual level betweenaflatoxin-albumin ad-
ducts, cell-mediated immune response tomalariaantigens, HBV
status, malaria infection, andethnic group (67). Twenty-five of
323 children (age 3-8 years) werepositive for HBsAg, and the
aflatoxin-adduct levels werehigher incarriers (logmean = 4.41,
SD = 0.95 pgAFBIlysineEq/mgalbumin) thannoncarriers (log
mean = 4.01, SD = 1.05; t -test: t = 1.78,p = 0.08). Multiple
regression analysis was performed to allow for confounding
variables, and the effect of HBsAg was then at the limit of
statistical significance (p = 0.05). Thisobservationsuggests that
current HBV infection increases theactivation ofaflatoxin, for-
mationofaflatoxin-albumin adducts, andconsequently thelevel
of DNA damage in the liver. These results are ofinterest with
respect to the studies performed inwoodchucks onthe influence
ofHBV on AFB, metabolism.
In a second study (68,69) in TheGambia, a detailed analysis
ofdietary intakeofaflatoxin overa7-dayperiod wascompared
with thelevelofalbumin-bound aflatoxinandtheurinary excre-
tion ofaflatoxin-7-guanine adduct in a group of20 individuals.
Ofthestudy subjects, 9 werechronic HBsAgcarriersand 11 were
noncarriers, and wherepossible the subjects werepaired forage,
sex, and food intake to examine thehypothesis as towhether, for
agiven intakeofaflatoxin, the level ofaflatoxin-protein and/or
DNAadductformation wasdifferent inthese twogroups. Infact,
in both the level ofaflatoxin-albumin adduct (69) and the ex-
creted aflatoxin-7-guanine adduct (68) there was no difference
between carriers and noncarriers as groups when adjusted for
dietary exposure, although there was considerable interin-
dividual variation. The small numbersofindividuals inthisstudy
should benoted. The studyofAllen etal. (67) alsodemonstrated
ahighly significant difference inaflatoxin-albumin adduct levels
in three majorethnic groups ofThe Gambia, which could have
a genetic basis in differences in AFB, metabolism.
The possibility thatAFB, could act via an immune suppres-
sion resulting in an increased susceptibility to chronic HBV in-
119120 WILDETAL.
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FIGURE 3. Aflatoxin, hepatitis B virus, and primary hepatocellular carcinoma: possible interactions.
fection has been a long-standing hypothesis (70). However,
despiteconsiderabledataontheimmune-suppressive action of
AFB, in animals and subsequent viral or parasitic infections
(71), to our knowledge no studies have specifically addressed
this question in animals with hepadna virus infection.
InthestudybyAllenetal. (67), thelevelofaflatoxin-albumin
was not related to any consistent effect on in vivo lymphopro-
liferative responses. In viomalaria-specific antibodytiters tend-
edtobe inversely correlatedwithaflatoxin-adductlevel, butthis
was not statistically significant. Thus, thesedatadid notprovide
any evidence foraneffectofaflatoxinexposure onthe immune
response inthesechildren. However, themarkerthatweusedfor
aflatoxin exposure is relatively shortterm (2-3 months), andthis
exposureperiodmay nothavebeenrelevanttotheimmunestatus
measured atthe sametime. Farmoreextensiveworkis required
to resolve this question, especially given the positive observa-
tions in animals (71).
Conclusions
The interaction betweenAFB, and HBV is an attractive pro-
posaltoexplaintheepidemiological observationsonPHCinhigh
risk areasofthe world, and several potential mechanisms have
been proposed. The data for these are summarized above and
represented schematically inFigure 3. Theactionsofbothagents
may be mutagenic and mitogenic at various stages ofthe car-
cinogenicprocesswiththeadditionalpossibility ofimmunesup-
pression by aflatoxin. Given the various effects of these two
agents onacell, noonespecific mechanism shouldbeexpected
toexplainallcasesofPHC. Despitetheplausabilityofaninterac-
tion between HBV and aflatoxin, from epidemiology and the
studies in transgenic mice, no strongevidence ofamechanism
ofinteractionhasbeenproduced. However, withtheavailabili-
tyofexperimental systemsandmolecularapproachesapplicable
to field studies, thetoolstoaddress this importantquestion are
now available.
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